Statistical analysis for evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
-
All rate and risk ratios given 95% confidence intervals
-
All p-values 2-sided
-
Intention-to-treat assumption
-
28-day mortality: evaluated with Hazard ratios (HR) from Cox regression (see 28-day mortality methods node for details) and tracked with a Kaplan-Meier curve
-
Time to discharge: modeled with Cox regression; those that died during hospitalization were right censored
-
Invasive mechanical ventilation or death (composite): No date information, so log-binomial regression used to estimate risk ratio
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Study design for evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Sample size and ending enrollment in evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Statistical analysis for evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
RECOVERY trial: a system for evaluating COVID-19 treatments